Contrast between Prevalence of HIT Antibodies and Confirmed HIT in Hospitalized COVID-19 Patients: A Prospective Study with Clinical Implications

Thromb Haemost. 2021 Jul;121(7):971-975. doi: 10.1055/a-1333-4688. Epub 2021 Jan 27.

Maxime Delrue^{1

2}, Virginie Siguret^{1

3}, Marie Neuwirth^{1

3}, Caren Brumpt¹, Sebastian Voicu^{4

5}, Ruxandra Burlacu⁶, Damien Sène⁶, Benjamin G Chousterman^{7

8}, Nassim Mohamedi⁹, Thomas Lecompte^{10

11}, Bruno Mégarbane^{4

5}, Alain Stépanian^{1

2}

¹ Hematology Laboratory, AP-HP Lariboisière Hospital, Paris University, Paris, France.
² EA 3518, Paris University, Paris, France.
³ INSERM UMRS 1140, Paris University, Paris, France.
⁴ Department of Medical and Toxicological Critical Care, AP-HP Lariboisière Hospital, Paris University, Paris, France.
⁵ INSERM UMRS 1144, Paris University, Paris, France.
⁶ Department of Internal Medicine, AP-HP Lariboisière Hospital, Paris University, Paris, France.
⁷ Department of Anesthesiology and Critical Care, AP-HP Lariboisière Hospital, Paris University, Paris, France.
⁸ INSERM UMRS 942, Université de Paris, Paris, France.
⁹ Department of Clinical Physiology, AP-HP Lariboisière Hospital, Paris University, Paris, France.
¹⁰ Département de Médecine, Service d'Angiologie et d'Hémostase, Hôpitaux Universitaires de Genève, Genève, Switzerland.
¹¹ Faculté de Médecine Geneva Platelet Group (GpG), Université de Genève, Geneva, Switzerland.

No abstract available

Publication types